Structure Therapeutics (NASDAQ:GPCR) Shares Down 4.5% - Should You Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares dropped 4.5% during trading on Thursday . The company traded as low as $21.69 and last traded at $21.70. Approximately 240,743 shares changed hands during trading, a decline of 72% from the average daily volume of 856,369 shares. The stock had previously closed at $22.72.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GPCR shares. William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Citigroup initiated coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. Finally, HC Wainwright decreased their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Buy" and an average price target of $76.50.

Structure Therapeutics Price Performance

The company has a 50 day simple moving average of $22.49 and a 200-day simple moving average of $24.76. The stock has a market capitalization of $1.28 billion, a P/E ratio of -29.98 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, equities analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in Structure Therapeutics by 45.1% in the 4th quarter. Principal Financial Group Inc. now owns 791,134 shares of the company's stock worth $21,456,000 after buying an additional 245,775 shares during the period. Handelsbanken Fonder AB purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth $4,475,000. Jones Financial Companies Lllp boosted its holdings in shares of Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock worth $115,000 after acquiring an additional 971 shares during the period. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after acquiring an additional 953 shares during the period. Finally, M&T Bank Corp grew its position in shares of Structure Therapeutics by 100.0% in the fourth quarter. M&T Bank Corp now owns 18,110 shares of the company's stock valued at $492,000 after purchasing an additional 9,055 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.